Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

John H. Krystal, G. Sanacora, H. Blumberg, A. Anand, D. S. Charney, G. Marek, C. N. Epperson, A. Goddard, G. F. Mason

Research output: Contribution to journalArticle

392 Citations (Scopus)

Abstract

Glutamate and γ-amino butyric acid (GABA) systems are emerging as targets for development of medications for mood disorders. There is increasing preclinical and clinical evidence that antidepressant drugs directly or indirectly reduce N-methyl-D-aspartate glutamate receptor function. Drugs that reduce glutamatergic activity or glutamate receptor-related signal transduction may also have antimanic effects. Recent studies employing magnetic resonance spectroscopy also suggest that unipolar, but not bipolar, depression is associated with reductions in cortical GABA levels. Antidepressant and mood-stabilizing treatments also appear to raise cortical GABA levels and to ameliorate GABA deficits in patients with mood disorders. The preponderance of available evidence suggests that glutamatergic and GABAergic modulation may be an important property of available antidepressant and mood-stabilizing agents. Future research will be needed to develop and evaluate new agents with specific glutamate and GABA receptor targets in the treatment of mood disorders.

Original languageEnglish (US)
JournalMolecular Psychiatry
Volume7
Issue numberSUPPL. 1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Butyric Acid
Antidepressive Agents
Glutamic Acid
Mood Disorders
Glutamate Receptors
Therapeutics
Antimanic Agents
Amino Acid Receptors
Excipients
N-Methyl-D-Aspartate Receptors
Bipolar Disorder
Signal Transduction
Magnetic Resonance Spectroscopy
Pharmaceutical Preparations

Keywords

  • Anticonvulsant
  • Bipolar disorder
  • Depression
  • Magnetic resonance spectroscopy
  • Metabotropic glutamate receptor
  • N-methyl-D-aspartate (NMDA)
  • Panic disorder
  • Premenstrual dysphoric disorder
  • Serotonin-2A receptor
  • Voltage-gated calcium channel

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health

Cite this

Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., ... Mason, G. F. (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Molecular Psychiatry, 7(SUPPL. 1). https://doi.org/10.1038/sj/mp/4001021

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. / Krystal, John H.; Sanacora, G.; Blumberg, H.; Anand, A.; Charney, D. S.; Marek, G.; Epperson, C. N.; Goddard, A.; Mason, G. F.

In: Molecular Psychiatry, Vol. 7, No. SUPPL. 1, 2002.

Research output: Contribution to journalArticle

Krystal, JH, Sanacora, G, Blumberg, H, Anand, A, Charney, DS, Marek, G, Epperson, CN, Goddard, A & Mason, GF 2002, 'Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments', Molecular Psychiatry, vol. 7, no. SUPPL. 1. https://doi.org/10.1038/sj/mp/4001021
Krystal, John H. ; Sanacora, G. ; Blumberg, H. ; Anand, A. ; Charney, D. S. ; Marek, G. ; Epperson, C. N. ; Goddard, A. ; Mason, G. F. / Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. In: Molecular Psychiatry. 2002 ; Vol. 7, No. SUPPL. 1.
@article{6efeb743b42540658f0f539331771c8e,
title = "Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments",
abstract = "Glutamate and γ-amino butyric acid (GABA) systems are emerging as targets for development of medications for mood disorders. There is increasing preclinical and clinical evidence that antidepressant drugs directly or indirectly reduce N-methyl-D-aspartate glutamate receptor function. Drugs that reduce glutamatergic activity or glutamate receptor-related signal transduction may also have antimanic effects. Recent studies employing magnetic resonance spectroscopy also suggest that unipolar, but not bipolar, depression is associated with reductions in cortical GABA levels. Antidepressant and mood-stabilizing treatments also appear to raise cortical GABA levels and to ameliorate GABA deficits in patients with mood disorders. The preponderance of available evidence suggests that glutamatergic and GABAergic modulation may be an important property of available antidepressant and mood-stabilizing agents. Future research will be needed to develop and evaluate new agents with specific glutamate and GABA receptor targets in the treatment of mood disorders.",
keywords = "Anticonvulsant, Bipolar disorder, Depression, Magnetic resonance spectroscopy, Metabotropic glutamate receptor, N-methyl-D-aspartate (NMDA), Panic disorder, Premenstrual dysphoric disorder, Serotonin-2A receptor, Voltage-gated calcium channel",
author = "Krystal, {John H.} and G. Sanacora and H. Blumberg and A. Anand and Charney, {D. S.} and G. Marek and Epperson, {C. N.} and A. Goddard and Mason, {G. F.}",
year = "2002",
doi = "10.1038/sj/mp/4001021",
language = "English (US)",
volume = "7",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

AU - Krystal, John H.

AU - Sanacora, G.

AU - Blumberg, H.

AU - Anand, A.

AU - Charney, D. S.

AU - Marek, G.

AU - Epperson, C. N.

AU - Goddard, A.

AU - Mason, G. F.

PY - 2002

Y1 - 2002

N2 - Glutamate and γ-amino butyric acid (GABA) systems are emerging as targets for development of medications for mood disorders. There is increasing preclinical and clinical evidence that antidepressant drugs directly or indirectly reduce N-methyl-D-aspartate glutamate receptor function. Drugs that reduce glutamatergic activity or glutamate receptor-related signal transduction may also have antimanic effects. Recent studies employing magnetic resonance spectroscopy also suggest that unipolar, but not bipolar, depression is associated with reductions in cortical GABA levels. Antidepressant and mood-stabilizing treatments also appear to raise cortical GABA levels and to ameliorate GABA deficits in patients with mood disorders. The preponderance of available evidence suggests that glutamatergic and GABAergic modulation may be an important property of available antidepressant and mood-stabilizing agents. Future research will be needed to develop and evaluate new agents with specific glutamate and GABA receptor targets in the treatment of mood disorders.

AB - Glutamate and γ-amino butyric acid (GABA) systems are emerging as targets for development of medications for mood disorders. There is increasing preclinical and clinical evidence that antidepressant drugs directly or indirectly reduce N-methyl-D-aspartate glutamate receptor function. Drugs that reduce glutamatergic activity or glutamate receptor-related signal transduction may also have antimanic effects. Recent studies employing magnetic resonance spectroscopy also suggest that unipolar, but not bipolar, depression is associated with reductions in cortical GABA levels. Antidepressant and mood-stabilizing treatments also appear to raise cortical GABA levels and to ameliorate GABA deficits in patients with mood disorders. The preponderance of available evidence suggests that glutamatergic and GABAergic modulation may be an important property of available antidepressant and mood-stabilizing agents. Future research will be needed to develop and evaluate new agents with specific glutamate and GABA receptor targets in the treatment of mood disorders.

KW - Anticonvulsant

KW - Bipolar disorder

KW - Depression

KW - Magnetic resonance spectroscopy

KW - Metabotropic glutamate receptor

KW - N-methyl-D-aspartate (NMDA)

KW - Panic disorder

KW - Premenstrual dysphoric disorder

KW - Serotonin-2A receptor

KW - Voltage-gated calcium channel

UR - http://www.scopus.com/inward/record.url?scp=0036212738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036212738&partnerID=8YFLogxK

U2 - 10.1038/sj/mp/4001021

DO - 10.1038/sj/mp/4001021

M3 - Article

VL - 7

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - SUPPL. 1

ER -